These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23608957)

  • 1. Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients.
    Kang YH; Lao HY; Wu H; Lai WH; Li XX; Yu XY; Chen JY; Zhong SL
    Eur J Clin Pharmacol; 2013 Aug; 69(8):1511-9. PubMed ID: 23608957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
    Tresukosol D; Suktitipat B; Hunnangkul S; Kamkaew R; Poldee S; Tassaneetrithep B; Likidlilid A
    PLoS One; 2014; 9(10):e110188. PubMed ID: 25329996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.
    Tang XF; Wang J; Zhang JH; Meng XM; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yuan JQ; Yang YJ
    Eur J Clin Pharmacol; 2013 May; 69(5):1103-12. PubMed ID: 23150151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of PON1 Gene Promoter DNA Methylation and Genetic Variations on the Clinical Outcomes of Dual Antiplatelet Therapy for Patients Undergoing Percutaneous Coronary Intervention.
    Lei HP; Yu XY; Wu H; Kang YH; Zhong WP; Cai LY; Zhang MZ; Chen JY; Mai LP; Ding QS; Yang M; Zhong SL
    Clin Pharmacokinet; 2018 Jul; 57(7):817-829. PubMed ID: 28875477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han.
    Wang JY; Zhang YJ; Li H; Hu XL; Li MP; Song PY; Ma QL; Peng LM; Chen XP
    Gene; 2018 Dec; 678():226-232. PubMed ID: 30096456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple genetic mutations increase the risk of thrombosis associated with clopidogrel after percutaneous coronary intervention.
    Jin H; Song J; Shen X; Liang Q; Sun G; Yu Y
    Pharmacogenomics; 2023 Mar; 24(4):227-237. PubMed ID: 36891827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
    Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T
    Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.
    Li X; Zhang L; Chen X; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Xu Q; Zhang Y; Li Y; Lu C; Yin T
    Thromb Res; 2013 Oct; 132(4):444-9. PubMed ID: 23993903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.
    Hokimoto S; Chitose T; Mizobe M; Akasaka T; Arima Y; Kaikita K; Iwashita S; Morita K; Miyazaki H; Oniki K; Matsui K; Nakagawa K; Ogawa H
    Eur J Clin Pharmacol; 2014 Jun; 70(6):667-73. PubMed ID: 24763934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.
    Trenk D; Hochholzer W; Fromm MF; Zolk O; Valina CM; Stratz C; Neumann FJ
    Circ Cardiovasc Genet; 2011 Aug; 4(4):429-36. PubMed ID: 21685174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients.
    Marchini JF; Pinto MR; Novaes GC; Badran AV; Pavão RB; Figueiredo GL; Lago IM; Lima-Filho MO; Lemos DC; Tonani M; Antloga CM; Oliveira L; Lorenzi JC; Marin-Neto JA
    Braz J Med Biol Res; 2017 Jan; 50(1):e5660. PubMed ID: 28076455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
    Hulot JS; Collet JP; Cayla G; Silvain J; Allanic F; Bellemain-Appaix A; Scott SA; Montalescot G
    Circ Cardiovasc Interv; 2011 Oct; 4(5):422-8. PubMed ID: 21972404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
    Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
    Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention.
    Zhang Z; Chen M; Zhang L; Zhao Q
    BMC Pharmacol Toxicol; 2020 Jan; 21(1):1. PubMed ID: 31900240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease.
    Zhu KX; Song PY; He-Li ; Li MP; Du YX; Ma QL; Peng LM; Chen XP
    Eur J Clin Pharmacol; 2021 Mar; 77(3):359-368. PubMed ID: 33089397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease.
    Arya V; Mahajan P; Saraf A; Mohanty A; Sawhney JP; Bhargava M
    Int J Lab Hematol; 2015 Dec; 37(6):809-18. PubMed ID: 26264906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paraoxonase-1 Q192R polymorphism is not associated with clopidogrel response in Chinese stroke patients.
    Yang J; Zhou JS; Tan J; He BS; Zou JJ
    Pharmazie; 2012 Dec; 67(12):1026-9. PubMed ID: 23346768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy.
    Arima Y; Kaikita K; Ishii M; Ito M; Sueta D; Oimatsu Y; Sakamoto K; Tsujita K; Kojima S; Nakagawa K; Hokimoto S; Ogawa H
    J Thromb Haemost; 2016 Apr; 14(4):850-9. PubMed ID: 26773298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.